Year None2024202320222021202020192018 Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) 4/30/2024 Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights 3/21/2024 Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program 1/5/2024 Information on the website may be out-of-date, that it is included for historical purposes only, and that the Company undertakes no duty to update the information.
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) 4/30/2024
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights 3/21/2024